EGFR and cancer: By selecting a cell cycle–targeted inhibitor, and cetuximab to direct the payload to EGFR-expressing cancer cells, we generated cetuximab–SNS-032 ADC, bearing a small fraction of the drug alone dose required to engender antitumor effects, and we evaluated this as a treatment against TNBC.